A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models
A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models
复制标题
DOI：
10.1080/02656730110116704
复制
发表时间：
2002-05-01
影响因子：
3.1
通讯作者：
Repasky, EA
中科院分区：
文献类型：
--
作者：
Kraybill, WG;Olenki, T;Repasky, EA
在动物肿瘤模型中的各种研究揭示了发热范围全身热疗（FR-WBH）用于癌症治疗的潜力。为了确定FR-WBH治疗在临床上的安全性，晚期实体瘤患者在门诊环境中使用Heckel-HT 2000设备加热至39- 39.5 ℃持续3或6小时，或39.5- 40 ℃持续6小时。这些WBH治疗耐受性良好，没有与心脏、肝脏、肾脏或肺部系统相关的显著不良事件。在大多数患者中，外周血白细胞群的流式细胞术分析表明，循环T淋巴细胞数量短暂减少，同时外周血中L-选择素阳性淋巴细胞数量减少。这些发现与之前在临床前小鼠研究中观察到的影响非常相似，在这些研究中，相同的发热样治疗显示出抑制肿瘤生长。这些研究已经确定了这种治疗的安全性，并将允许未来的临床试验，其中FR-WBH治疗的应用可以与其他抗癌疗法相结合，包括免疫疗法和化疗。
Various studies in animal tumour models have revealed the potential of fever-range whole body hyperthermia (FR-WBH) to be used in cancer therapy. To determine the safety of FR-WBH treatment in the clinic, patients with advanced solid tumours were heated in the outpatient setting to 39-39.5degreesC for 3 or 6 h, or 39.5-40degreesC for 6 h using the Heckel-HT 2000 apparatus. These WBH treatments were well tolerated, with no significant adverse events related to cardiac, hepatic, renal or pulmonary systems. In the majority of patients, flow cytometric analysis of peripheral blood leukocyte populations indicated that there were transient decreases in the number of circulating T lymphocytes and a concomitant decrease in the number of L-selectin positive lymphocytes in the peripheral blood. These findings closely mimic the affects seen previously in pre-clinical murine studies in which this same fever-like treatment was shown to inhibit tumour growth. These studies have established the safety of this treatment and will allow for future clinical trials where application of FR-WBH treatment can be combined with other anti-cancer therapies, including immunotherapy and chemotherapy.